title: ERalpha-negative and triple negative breast cancer: molecular features and potential therapeutic approaches.
abstract: Triple negative breast cancer (TNBC) is a type of aggressive breast cancer lacking the expression of estrogen receptors (ER), progesterone receptors (PR) and human epidermal growth factor receptor-2 (HER-2). TNBC patients account for approximately 15% of total breast cancer patients and are more prevalent among young African, African-American and Latino women patients. The currently available ER-targeted and Her-2-based therapies are not effective for treating TNBC. Recent studies have revealed a number of novel features of TNBC. In the present work, we comprehensively addressed these features and discussed potential therapeutic approaches based on these features for TNBC, with particular focus on: 1) the pathological features of TNBC/basal-like breast cancer; 2) E(2)/ERbeta-mediated signaling pathways; 3) G-protein coupling receptor-30/epithelial growth factor receptor (GPCR-30/EGFR) signaling pathway; 4) interactions of ERbeta with breast cancer 1/2 (BRCA1/2); 5) chemokine CXCL8 and related chemokines; 6) altered microRNA signatures and suppression of ERalpha expression/ERalpha-signaling by micro-RNAs; 7) altered expression of several pro-oncongenic and tumor suppressor proteins; and 8) genotoxic effects caused by oxidative estrogen metabolites. Gaining better insights into these molecular pathways in TNBC may lead to identification of novel biomarkers and targets for development of diagnostic and therapeutic approaches for prevention and treatment of TNBC.
authors.affiliation: Breast Cancer Research Laboratory, Fox Chase Cancer Center, Philadelphia, PA 19111, USA. jinqiang.chen@fccc.edu
authors.forename: Jin-Qiang
authors.initials: JQ
authors.lastname: Chen
authors.forename: Jose
authors.initials: J
authors.lastname: Russo
mesh_terms: D001943:Breast Neoplasms / Q000737:chemistry* / Q000188:drug therapy / Q000378:metabolism; D015820:Cadherins / Q000032:analysis; D019743:Chemokines, CXC / Q000502:physiology; D019040:E-Selectin / Q000032:analysis; D066246:ErbB Receptors / Q000502:physiology; D047628:Estrogen Receptor alpha / Q000032:analysis*; D047629:Estrogen Receptor beta / Q000032:analysis / Q000502:physiology; D004967:Estrogens / Q000378:metabolism / Q000633:toxicity; D005260:Female; D006801:Humans; D035683:MicroRNAs / Q000502:physiology; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000032:analysis*; D051880:Receptors, Notch / Q000502:physiology; D011980:Receptors, Progesterone / Q000032:analysis*; D015398:Signal Transduction
chemical_list: D015820:Cadherins; D019743:Chemokines, CXC; D019040:E-Selectin; D066246:ErbB Receptors; D047628:Estrogen Receptor alpha; D047629:Estrogen Receptor beta; D004967:Estrogens; D035683:MicroRNAs; D018719:Erb-b2 Receptor Tyrosine Kinases; D051880:Receptors, Notch; D011980:Receptors, Progesterone; C508053:ERBB2 protein, human